3D Printing of Bilayer Tablets: A Comprehensive Review of Technologies, Formulations, and Applications

Keywords

Abstract

References

1. [1]REFERENCE
2. [2]1. Agiba AM, Abul-Ella SS, Abd El-Monem RA. Pharmacotechnical development and optimization of multilayered tablets: An updated industrial review with emphasis on bilayer tablets. Int J Appl Pharm.2021;13:55-64
3. [3]2. Sadia M, Isreb A, Abbadi I, Isreb M, Aziz D, Selo A,mmins P, Alhnan MA. From ‘fixed dose combinations’ to ‘a dynamic dose combiner’: 3D printed bi-layer antihypertensive tablets. Eur J Pharm Sci. 2018;123:484-9
4. [4]3. Goyanes A, Buanz AB, Hatton GB, Gaisford S, Basit AW. 3D printing of modified-release aminosalicylate (4-ASA and 5-ASA) tablets. Eur J Pharm Biopharm. 2015;89:157-62.
5. [5]4. Aprecia Pharmaceuticals. Spritam (levetiracetam): first FDA-approved 3D-printed drug product [Internet]. Warren (NJ): Aprecia Pharmaceuticals; 2015 [cited 2024 Jan 10]. Available from: https://www.aprecia.com.
6. [6]5. Hossain KR, Jami MM, Shyeed A, Khatun K, Hasan K, Cobra K, Ahmed F. Application of 3D printing in medicine: Technologies and challenges. Al-bahir J Eng Pure Sci. 2023;3(1):7.
7. [7]6. Khaled SA, Burley JC, Alexander MR, Yang J, Roberts CJ. 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. J Control Release.2015;217:308-14.
8. [8]7. Pereira BC, Isreb A, Forbes RT, Dores F, Habashy R, Petit JB, et al. 'Temporary Plasticiser': a novel solution to fabricate 3D printed patient-centred cardiovascular 'polypill' architectures. Eur J Pharm Biopharm. 2019;135:94-103.
9. [9]8. Curti C, Kirby DJ, Russell CA. Current formulation approaches in design and development of solid oral dosage forms through three-dimensional printing, Prog. Addit Manuf.2020;5:111-123.
10. [10]9. Dimitrov M, Georgieva D, Ilieva S, Petkova V. The era of digital pharmacy. 3D printing-realities and perspectives. Pharmacia.70 (4):1083–1092.
11. [11]10. Jamróz W, Szafraniec J, Kurek M, Jachowicz R. 3D printing in pharmaceutical and medical applications: recent achievements and challenges. Pharm Res. 2018;35(9):176.
12. [12]11. Chakka LRJ, Chede S. 3D printing of pharmaceuticals for disease treatment. Front Med Technol. 2022;4:1040052.
13. [13]12. Sharma P, Jain V. An overview of current advances and pharmaceutical uses of 3D and 4D printing. Explor Med. 2023;4(4):560-575.
14. [14]13. Korte C, Quodbach J. Formulation development and 3D printing of bilayer tablets via fused deposition modeling. Int J Pharm. 2018;548(1):310-319.
15. [15]14. Zhang J, et al. Investigation of the fused deposition modeling additive manufacturing i: influence of process temperature on the quality and crystallinity of the dosage forms. AAPS PharmSciTech. (2021) 22(8):258.
16. [16]15. Goyanes A, Kobayashi M, Martinez-Pacheco R, Gaisford S, Basit AW. Fused-filament 3D printing of drug products: microstructure analysis and drug release characteristics of PVA-based caplets. Int J Pharm. 2016;514(1):290-5.
17. [17]16. Crișan AG, Porfire A, Iurian S, Casian T, Muntean DM, Gâvan A, et al. Development of a bilayer tablet by fused deposition modeling as a sustained-release drug delivery system. Pharmaceuticals. 2023;16(9):1321.
18. [18]17. Tan DK, Maniruzzaman M, Nokhodchi A. Advanced pharmaceutical applications of hot-melt extrusion coupled with fused deposition modelling (FDM) 3D printing for personalised drug delivery. Pharmaceutics. 2018;10(4):203.
19. [19]18. Charoo NA, Barakh Ali SF, Mohamed EM, Kuttolamadom MA, Ozkan T, Khan MA,Rahman Z et al. Selective laser sintering 3D printing – an overview of the technology and pharmaceutical applications. Drug Dev. Ind. Pharm. 2020;46 (6):869–877.
20. [20]19. Fina, F, Goyanes A, Gaisford S, Basit AW. 2017.Selective laser sintering (SLS) 3D printing of medicines. Int J Pharm.2017;529 (1–2):285–293.
21. [21]20. Junqueira LA, Tabriz GA, Vivek Garg, Kolipaka SS, Ho-Wah Hui, Boersen N, Roberts S, Jones J, Douroumis D. Selective laser sintering for printing bilayer tablets. Int J Pharma. 2025;670:125116.
22. [22]21. Allahham N, Fina F, Marcuta C, Kraschew L, Mohr W, Gaisford S, et al. Selective laser sintering 3D printing of orally disintegrating printlets containing ondansetron. Pharmaceutics. 2020;12(2):110.
23. [23]22. Junqueira LA, Tabriz AG, Garg V, Kolipaka SS, Hui HW, Boersen N, Roberts S, Jones J, Douroumis D. Selective laser sintering for printing bilayer tablets. Int J Pharm. 2025 ;670:125116.
24. [24]23. Seoane-Viaño I, Januskaite P, Alvarez-Lorenzo C, Basit AW, Goyanes A. Semi-solid extrusion 3D printing in drug delivery and biomedicine: towards printing of 3D cells and tissues. J Control Release. 2021;332:667-684.
25. [25]24. Vojinovic A, Medarevik D, Stanojevic G, Mircovic D, Mugosa S, Adamov I et al. Development and evaluation of 3D-printed losartan potassium tablets using semi-solid extrusion: The effect of geometry, drug loading and superdisintegrant. Pharmaceuticals. 2025;18(10):1504.
26. [26]25. Mathiyalagan R, Westerlund M, Mahran A, Altunay R, Suuronen J, Palo M et al. 3D printing of tailored veterinary dual-release tablets: a semi-solid extrusion approach. RSC Pharm Med. 2025;4:322.
27. [27]26. Muehlenfeld C, Duffy P, Yang F, Zermeño Pérez D, El-Saleh F, Durig T. Excipients in Pharmaceutical Additive Manufacturing: A comprehensive exploration of polymeric material selection for enhanced 3D printing. Pharmaceutics. 2024; 16(3):317.
28. [28]27. Lee S, Song ES, Lee E, Kwon G, Kim DW. Tunable drug release from 3d-printed bilayer tablets: combining hot-melt extrusion and fused deposition modeling. Polymers. 2026; 18(2):210.
29. [29]28. Prasad E, Islam MT, Goodwin DJ, Megarry AJ, Halbert GW, Florence AJ, et al. Development of a hot-melt extrusion (HME) process to produce drug loaded Affinisol HPMC HME filaments for fused deposition modelling (FDM) 3D printing. Addit Manuf. 2019;29:100776.
30. [30]29. Sadia M, Sosnicka A, Arafat B, Isreb A, Ahmed W, Kelarakis A, et al. Adaptation of pharmaceutical excipients to FDM 3D printing for the fabrication of patient-tailored immediate release tablets. Int J Pharm. 2016;513(1-2):659-68.
31. [31]30. Melocchi A, Parietti F, Maroni A, Foppoli A, Gazzaniga A, Zema L. Hot-melt extruded filaments based on pharmaceutical grade polymers for 3D printing by fused deposition modeling. Int J Pharm. 2016;509(1-2):255-63.
32. [32]31. Prasad E, Islam MT, Goodwin DJ, Megarry AJ, Halbert GW, Florence AJ, et al. Development of a hot-melt extrusion (HME) process to produce drug loaded Affinisol HPMC HME filaments for fused deposition modelling (FDM) 3D printing. Addit Manuf. 2019;29:100776.
33. [33]32. Sadia M, Sosnicka A, Arafat B, Isreb A, Ahmed W, Kelarakis A, et al. Adaptation of pharmaceutical excipients to FDM 3D printing for the fabrication of patient-tailored immediate release tablets. Int J Pharm. 2016;513(1-2):659-68.
34. [34]33. Markl D, Zeitler JA. A review of non-destructive analytical techniques for quality by design-based 3D printed pharmaceuticals. Adv Drug Deliv Rev. 2017;117:112-132.
35. [35]34. Windolf H, Chamberlain R, Quodbach J. Predicting drug release from 3D printed oral medicines based on solid-state properties and spatial distribution. Int J Pharm. 2021;597:120395.
36. [36]35. Tabriz AG, Nandi U, Hurt AP, Hui HW, Karki S, Gong Y, et al. 3D printed bilayer tablet with dual controlled drug release for tuberculosis treatment. Int J Pharm. 2021;593:120147.
37. [37]36. Sadia M, Isreb A, Abbadi I, Isreb M, Aziz D, Selo A, et al. From 'fixed dose combinations' to a 'dynamic dose combiner': 3D printed bi-layer antihypertensive tablets. Eur J Pharm Sci. 2018;123:484-494.
38. [38]37. Crişan AG, Porfire A, Iurian S, Rus LM, Sadia M, Isreb A, Abbadi I, Isreb M, Aziz D, Selo A, et al. From 'fixed dose combinations' to a 'dynamic dose combiner': 3D printed bi-layer antihypertensive tablets. Eur J Pharm Sci. 2018;123:484-494.
39. [39]38. Lucăcel Ciceo R, Turza A, et al. Development of a bilayer tablet by fused deposition modeling as a sustained-release drug delivery system. Pharmaceuticals. 2023;16(9):1321.
40. [40]39. Lalitha KA, Raghava D, Rao NK, Sravani NP. Regulatory hurdles in the commercialization of 3D printed pharmaceuticals and medical devices. J Cardiovasc Dis Res. 2025;16(10):139-145.
41. [41]40. Joshi D, Shukla P, Choudhary NK. Enhancing pharmaceutical 3D printing throughQuality-by-Design (QbD): Challenges, strategies, and regulatory insights. Int J Newgen Res Pharm Healthc. 2025;3(1):158-168.
42. [42]41. Cader HK, et al. Non-destructive analytical techniques and Process Analytical Technology (PAT) for 3D printed pharmaceuticals. J Pharm Biomed Anal. 2020;189:113426.
43. [43]42. Awad A, et al. A case study on decentralized manufacturing of 3D printed medicines: Integration of inline NIR spectroscopy. Int J Pha

Authors (2)